1674 results about "Endogeny" patented technology

Provided herein are methods, compositions, and kits for determining the spatial location of target nucleic acids, including endogenous and exogenous target nucleic acids, in a biological sample using padlock probes and substrates with spatially barcoded capture probes. Also disclosed herein are methods for determining a presence and / or location of a microbe (e.g., archaea, fungi, bacteria) in a biological sample, e.g., by determining the presence and / or location of a microbial target nucleic acid in the biological sample.

The invention discloses a gene and a protein for adjusting tobacco polyphenol aroma substances and application of the gene and the protein. The gene is a tobacco NtMYB28 gene, and the CDS sequence of the tobacco NtMYB28 gene is as shown in SEQ ID No. 1. The invention further discloses application of the tobacco NtMYB28 gene in regulating the content of endogenous polyphenol substances in tobacco and regulating and controlling the metabolic pathway of phenylpropane in tobacco. The key gene NtMYB28 capable of simply and effectively adjusting the content of polyphenol substances in tobacco and the metabolic pathway of phenylpropane is found, and the gene can be applied to efficient cultivation of new high-aroma tobacco materials and development and utilization of new high-value functional tobacco germplasm.

The invention provides an enhancer RNA (Ribonucleic Acid) molecule MZGAe1 and application thereof, and relates to the technical field of biology. The invention provides an enhancer RNA (Ribonucleic Acid) molecule MZGAe1. The nucleotide sequence of the enhancer RNA molecule MZGAe1 is as shown in SEQ ID NO: 1; meanwhile, the invention further provides a specific sgRNA sequence for activating the molecule in a targeted manner and a recombinant vector of the specific sgRNA sequence. Expression of endogenous MZGAe1 of cells is specifically activated by adopting a CRISPR activation technology, and conversion of mouse embryonic stem cells to bicellular-like cells can be efficiently promoted. By providing a brand-new endogenous targeted MZGAe1 accurate activation tool, the efficient transformation of wild mouse embryonic stem cells to bicellular cells can be realized only under the condition of endogenous activation of single enhancer RNA molecule MZGAe1, the proportion is at least increased by 5%, the expression of a totipotent marker gene ZSCAN4 is activated, and the expression of the totipotent marker gene ZSCAN4 is promoted. And an efficient and specific brand-new research tool and scheme are provided for researching zygote genome activation, embryonic development early events and cell reprogramming.

Aiming at the challenge of osteochondral defect repair, the invention provides a preparation method of a fiber-reinforced self-repairing hydrogel scaffold (SBPS). According to the method, phenylboronic acid modified sodium alginate, polyvinyl alcohol and fibroin nanofibers rich in beta-Sheet are utilized to form the hydrogel through dynamic boric acid ester bonds and hydrogen bonds. The SBPS hydrogel loaded with PDGF-BB is combined with the nanosheet containing LDH / ChS / TGF-beta3, so that multi-dimensional synergy of mechanical strengthening, sequential drug release (PDGF-BB is released in an early stage and TGF-beta3 / Mg < 2 + > is released in a later stage), ROS removal and endogenous repair is realized. The Mg < 2 + > concentration gradient effect further assists staged regulation (vascularized bone regeneration-cartilage matrix synthesis), and breaks through the limitation of a single factor. Experiments prove that the scaffold can effectively drive angiogenesis, stem cell recruitment and cartilage / bone differentiation in vivo and in vitro, and finally osteochondral regeneration with structure-function matching is achieved.

The invention belongs to the technical field of battery dressings, and particularly relates to a wearable magnesium battery self-powered dressing for chronic wound healing and a preparation method and application thereof. A flexible conductive carbon cloth coated with a viologen-based covalent organic framework material is used as a battery positive electrode, a magnesium sheet is used as a negative electrode, polyacrylamide hydrogel is used as a solid electrolyte, and the flexible wearable self-powered dressing is assembled. The formed electrode can effectively input electrical stimulation to the wound surface, the dressing can simulate an endogenous electric field in the wound, induce migration of fibroblasts, regulate the immune microenvironment of the wound and inhibit inflammatory response, polyacrylamide is used as gel electrolyte, and the dressing has good hygroscopicity, can absorb exudate at the wound surface and keep a wet healing environment, and can be applied to the wound healing. The chronic wound healing of the rat is effectively promoted. The self-powered dressing prepared by the invention provides a reliable electrotherapy method for chronic wound healing.

The invention belongs to the technical field of microorganisms, and particularly relates to bacillus amyloliquefaciens with high H2O2 yield and application of the bacillus amyloliquefaciens. According to the bacillus amyloliquefaciens C-50-11, H2O2 can be continuously generated in the high-temperature period of compost, H2O2 free radicals can oxidize and decompose complex organic matter to promote humus condensation in a mediated mode, the content of humus in the compost in the high-temperature period is further effectively increased, and compared with the content of humus in uninoculated compost, the content of the humus after inoculation is increased by 20% or above. According to the method disclosed by the invention, chemical degradation is realized by combining an endogenous H2O2 strengthening effect of thermophilic bacteria and utilizing an oxidizing agent generated by organisms, so that the condition of a high-temperature period of compost is fully utilized, and a new method way is provided for increasing the content of humus in the compost.

The application discloses a specific palmitoyl transferase inhibitor and application thereof, and an active ingredient of the palmitoyl transferase inhibitor is 4-(3-(2-(trifluoromethyl)-9H-thioxanthene-9-ylidene)propyl)-1-piperazine ethanol or a salt thereof. Current palmitoylation inhibitors, 2-bromohexadecanoic acid (2-BP), cerulenin and tunicamycin can all inhibit protein palmitoylation in cells, but all are not selective. And the existing palmitoylation inhibitors are similar to endogenous fatty acids, and inevitably affect lipid metabolism in the body, which limits the clinical application. The application discloses, for the first time, the application of 4-(3-(2-(trifluoromethyl)-9H-thioxanthene-9-ylidene)propyl)-1-piperazine ethanol as a specific palmitoyl transferase inhibitor, and the palmitoyl transferase inhibitor is better in specificity and reversible in inhibition.

The invention discloses a Taq DNA polymerase mutant as well as a preparation method and application thereof, and relates to the technical field of biology. The Taq DNA polymerase mutant is mutation on the basis of a wild type Taq DNA polymerase amino acid sequence as shown in SEQ ID NO.1, and comprises at least one of amino acid mutation L345E, L352D and S438M. The Taq DNA polymerase mutant has excellent tolerance to urea, and solves the dual technical problems that complex biological samples containing endogenous inhibitors such as urea can be efficiently amplified, and the Taq DNA polymerase mutant is compatible with difficult PCR reactions which take urea as an additive to optimize a high GC template and the like. Therefore, the mutant is a molecular biology tool enzyme which is wider in applicability and more stable and reliable in performance.

The invention discloses clostridium butyricum as well as a culture method and application thereof, belongs to the field of feed additives, and aims to solve the problems that a controllable fattening period is shortened and the efficacy of the clostridium butyricum cannot be completely exerted due to the fact that a wide range of clostridium butyricum needs a relatively long adaptation period for an endogenous intestinal environment of an animal. The clostridium butyricum from the North Naa Biotechnology Co., Ltd. Is cultured by simulating an animal endogenous environment in vitro, and after the clostridium butyricum which completely adapts to animal endogenous is obtained, the screened animal endogenous clostridium butyricum is coated by adopting a coating technology, so that the clostridium butyricum is not damaged by a strong acid environment in an animal stomach bag; the clostridium butyricum strain has the advantages that the clostridium butyricum strain can be used for preparing animal endogenous clostridium butyricum, a large quantity of animal endogenous clostridium butyricum can reach intestinal tracts and be released, and the animal endogenous clostridium butyricum can quickly adapt to animal intestinal environment due to higher adaptability of the strains, and can quickly form efficient colonization and functional expression under the condition of almost no adaptation period. The feed additive can be used as a biological feed additive.

The invention discloses a recombinant halomonas for producing polyhydroxyalkanoate as well as a construction method and application of the recombinant halomonas. The recombinant halomonas comprises an exogenous gene, the exogenous gene comprises a combination of an aldD gene, a dhaT gene and an orfz gene, and the recombinant halomonas weakens the expression of an endogenous prpc gene. According to the invention, a P34HB synthesis route is successfully constructed through a synthesis route of exogenous introduction from 1, 4-butanediol (BDO) to 4-hydroxybutyryl coenzyme A, the proportion of each monomer in the copolymer can be effectively regulated and controlled, especially after exogenous addition of short-chain fatty acids (such as formic acid, acetic acid, propionic acid, butyric acid and the like), the synthesis of copolymers such as PHB, PHBV, P34HB, P34HB3HV and the like can be further improved, and the synthesis efficiency of the copolymer is improved. And the proportion of different monomers is adjusted, so that the diversity and yield of the copolymer are enhanced.

The present disclosure, in some aspects, relates to antisense oligonucleotides (ASO) for use in the prevention or treatment of a disease or a condition associated with low- density lipoprotein (LDL) in a subject. In some embodiments, the ASO effects site-directed adenosine-to-inosine (A-to-l) editing of a target adenosine in a target RNA sequence derived from a sequence of an endogenous low-density lipoprotein receptor (LDLR) gene such that: a) the modified LDLR protein has: (i) reduced binding to the inducible degrader of the LDLR protein (IDOL); (ii) increased stability; (iii) improved resistance to IDOL-mediated degradation; (iv) increased LDLR protein expression; and / or (v) increased activity or function to take up LDL; and / or b) editing of the 3'-untranslated region (UTR) of the target RNA leads to an increase in LDLR protein expression and / or stability.

The invention discloses a magnesium-containing nanoparticle modified biological scaffold composite material as well as a preparation method and application thereof. The magnesium-containing nano particle modified biological scaffold composite material comprises a biological scaffold material and magnesium-containing nano particles modified on the biological scaffold material, the magnesium-containing nano particles comprise nano magnesium oxide particles and / or nano magnesium oxide-polyphenol compound particles, the nano magnesium oxide-polyphenol compound particles are of a shell-core structure, and the shell-core structure is of a hollow structure. Comprising magnesium oxide serving as a core and a polyphenol compound shell layer coating the surface of the magnesium oxide. The magnesium-containing nanoparticle-modified biological scaffold composite material provided by the invention can prolong the degradation and release of magnesium ions, promote improvement of microenvironment problems such as inflammation and active oxygen outbreak after spinal cord injury, regulate and control oxidative stress and inflammatory response, promote nerve regeneration and motor function recovery, and improve the survival rate of spinal cord injury. The problem that nanoparticles stop in a spinal cord injury area is effectively solved, and support is provided for migration, growth and differentiation of endogenous neural stem cells.

The invention discloses a chemiluminescence heparin binding protein kit and a determination method thereof. The kit comprises reagent components of a reagent R1, a reagent R2 and a reagent R3, as well as a matched calibrator, a matched quality control product, a matched pre-excitation liquid, a matched excitation liquid and a matched cleaning liquid, wherein the reagent R1 contains magnetic particles coated with streptavidin, and the reagent R2 and the reagent R3 are respectively monoclonal antibodies which are labeled by acridinium ester and biotin and are used for recognizing different epitopes of human HBP. The kit shows better sensitivity, wider detection range and high specificity, and can effectively reduce potential endogenous and exogenous interference in clinical samples of potential interference people.

The invention relates to the technical field of insulating oil purification, and particularly discloses a deep purification and performance improvement method of vegetable insulating oil, which comprises the following steps: determining fluorination parameters through molecular dynamics simulation, carrying out surface fluorination modification on a polypropylene filter membrane, and constructing a high-coverage C-F bond layer; specific endogenous impurities such as gossypol, phospholipid and pigment in the vegetable insulating oil such as cotton seeds can be effectively removed, and the problems of oxidation acceleration, insulation performance reduction and equipment aging caused by the specific endogenous impurities are avoided; and a core technical support is provided for long-acting stable operation of the vegetable insulating oil.

The present invention relates to antisense oligonucleotides (AONs) that can mediate RNA editing by binding to a target RNA nucleic acid molecule, preferably an RNA transcript molecule, in a cell and recruiting an endogenous deaminating enzyme in the cell to deaminate a target adenosine in the target RNA molecule to an inosine. The target RNA molecule is a transcript molecule form the SLC10A1 gene that encodes the Na+ / Taurocholate Co-transporting Polypeptide (NTCP), and the target adenosine is the adenosine in the GAC codon coding for aspartic acid (D) at position 24 of the NTCP protein. The deamination of the adenosine changes the amino acid to a glycine (G). The RNA editing of the adenosine will result in a loss-of-function of the NTCP protein, which will result in lowered uptake of bile acids from the portal circulation into the liver, thereby lowering the risk of suffering from disorders related to bile accumulation in the liver.

A method for haematopoietic stem and / or progenitor cell (HSPC) transplantation in a subject in need thereof, comprising the steps: (a) administering one or more HSPC mobiliser to the subject to mobilise the subject's endogenous HSPCs; and (b) administering a population of HSPCs to the subject.

The present invention discloses CLDN18.2-targeting antibodies, bispecific antibodies and use thereof. The CLDN18.2-targeting antibody is a single-domain heavy-chain antibody that has high affinity for tumor cells endogenously expressing CLDN18.2 and can induce high endocytic activity. The bispecific antibody can target CLDN18.2 and CD3 and retains the binding effect of an Fc to an FcRn; meanwhile, a mutant Fc is preferred so as to reduce the binding to an FcgR and thus the activation of non-specific T cells caused by the cross-linking of an FcgR. The CD3-terminus activity is optimized so that the release of common cytokines in CRS, such as IL6 and TNFα can be reduced.

The present disclosure relates to engineered RNA m6A demethylases with disrupted low complexity regions (LCRs) for expression in plants, as well as recombinant DNA encoding the engineered RNA m6A demethylases, vectors encoding the recombinant DNA, plants including the engineered RNA m6A demethylases, and method of improving the growth of plants using the engineered RNA m6A demethylases, including increased root growth and elevated photosynthesis. The present disclosure further relates to methods of improving growth of a plant, including increased root growth and elevated photosynthesis, by modifying endogenous ALKBH5 homolog genes to include disrupted LCRs, and plants produced by those methods.

The invention belongs to the field of biological medicine and material science, and particularly relates to an intelligent response type piezoelectric nanofiber dressing and a preparation method and application thereof. According to the preparation method, polyvinylidene fluoride-trifluoroethylene, a high polymer material and inorganic nanoparticles are blended and spun through an electrostatic spinning technology, and then a photo-thermal component coating is subjected to surface in-situ oxidation and self-polymerization, so that the composite fiber membrane is prepared. Under the stimulation of ultrasound (US) and near-infrared laser (Laser), the fiber membrane can cooperatively activate the piezoelectric effect and the photothermal effect, generate a dynamic electric field and local high temperature, realize multi-mode cooperative killing of bacteria (the antibacterial rate exceeds 99%), and simulate an endogenous electric field to promote cell migration and wound healing. The dressing has good mechanical properties (the Young modulus is 15-20 MPa), hydrophilicity (the contact angle is about 30 degrees), biocompatibility and stability, is suitable for treatment of chronic infected wounds such as diabetes mellitus and the like, and has the advantages of on-demand activation and intelligent response.

The invention discloses a plant lactobacillus with light aging resistance and an application thereof. The preservation number of the plant lactobacillus cj001 disclosed by the invention is CGMCC (China General Microbiological Culture Collection Center) No.35419. The fermentation supernatant of the plant lactobacillus cj001 shows good anti-aging activity and in-vitro antioxidant activity, and the growth ability of HaCaT cells is promoted. After the combined fermentation product of the plant lactobacillus cj001 and the lactobacillus paracasei Grx701 is subjected to ultraviolet radiation, the proliferation of HaCaT cells can be promoted, the endogenous antioxidant capacity of human skin cells can be enhanced, the photooxidation damage can be effectively relieved, and the combined fermentation product has a wide application value in the field of preparation of products with antioxidant, anti-aging, anti-ultraviolet damage, anti-photoaging and the like.

The invention discloses bi-crosslinking self-reinforced hydrogel based on endogenous glucose in-situ initiation as well as a preparation method and application of the bi-crosslinking self-reinforced hydrogel, and relates to the technical field of biomedical materials. The double-crosslinking self-enhanced hydrogel is prepared from the following components in concentration: 1 to 3 weight percent of hyaluronic acid-tyramine, 0.8 to 1.2 weight percent of sodium alginate, 1 to 100 mmol / L of calcium carbonate, 0.0001 to 10 U / mL of horse radish peroxidase, 20 to 40 U / mL of glucose oxidase and the balance of ultrapure water. The invention also discloses an application of the double-crosslinking self-reinforced hydrogel in preparation of a filling and repairing product for soft tissue defects. The hydrogel disclosed by the invention can be filled in a tissue defect part in an injection manner, glucose in body fluid is utilized to initiate crosslinking in situ to form the hydrogel with excellent mechanical properties and long-term stability, and meanwhile, the hydrogel is good in biocompatibility and relatively high in application value.

The invention belongs to the technical field of medical biological materials, and particularly relates to a sodium hyaluronate gel regeneration filler for injection and a preparation method and application thereof.The sodium hyaluronate gel serves as a carrier to disperse acellular matrix particles, the sodium hyaluronate gel forms a micron-sized porous structure in the cross-linking process through a microbubbling technology, and the sodium hyaluronate gel is prepared into the sodium hyaluronate gel regeneration filler for injection and the preparation method and application of the sodium hyaluronate gel regeneration filler. A local cross-linked network is strengthened by combining a secondary cross-linking process, high elastic modulus is realized while the content of sodium hyaluronate is reduced, so that the porous structure has excellent instant filling and shaping capability and controllable degradation behavior, the porous structure can promote permeation of hyaluronidase, the degradation period of the hyaluronidase is matched with the tissue regeneration process, and the tissue regeneration effect is improved. And the acellular matrix particles can continuously induce adhesion, migration, proliferation and differentiation of endogenous cells of tissues, synergistically promote in-situ tissue regeneration, effectively reduce repeated injection requirements and reduce long-term complication risks, and have a good application prospect in soft tissue filling and repairing.

The invention provides recombinant humanized elastin with an effect of improving endogenous skin aging and application of the recombinant humanized elastin, and belongs to the technical field of crossing of dermatology and biological materials. The recombinant humanized elastin is based on a human elastin core function sequence, recombinant optimization and efficient expression are carried out by adopting a synthetic biological strategy, and excellent stability and biological activity are shown. The recombinant humanized elastin can be used for constructing a skin repair dressing, and synergistically improves endogenous aging characteristics such as skin elasticity reduction, collagen loss and high oxidative stress by remodeling an extracellular matrix network structure. Animal experiments prove that a product based on the recombinant humanized elastin has good tissue repair capacity, biocompatibility and antioxidant activity, and can be widely applied to functional skin care products and medical cosmetic preparations.

This disclosure relates methods for expanding γδ T cells. More specifically, the disclosure relates to methods of expanding γδ T cells that have an eliminated or reduced expression of endogenous MHC Class I molecules, by expressing a single-chain fusion HLA Class I protein. In some embodiments, the endogenous B2M gene of the γδ T cells is disrupted. In some embodiments, the single-chain fusion HLA Class I protein includes at least a portion of B2M protein and at least a portion of HLA-E heavy chain.

To provide a method for determining when a natural therapeutic or beneficial product will exert its therapeutic or beneficial effect via a physiological mechanism of action.SOLUTION: The present invention relates to a new method that allows the evolution of medical technologies from the use of chemically or biologically defined artificial substances to self-assembling natural products obtained from natural raw materials by industrial processes that preserve their endogenous properties, thereby preserving their ability to interact with the networks of the living world (including humans), which natural products cannot be defined with classical qualitative and quantitative composition schemes. Thus, the present invention provides a new method for determining when a therapeutic or beneficial product exerts its therapeutic or beneficial effect via a physiological mechanism of action. This method provides the tools necessary for the skilled person to assess the mechanism of action of a therapeutic or beneficial product, which has become a relevant feature to assess with new developments in regulatory regimes for medical devices and nutraceuticals, for which there is no method available in the art.SELECTED DRAWING: None

The invention belongs to the technical field of genetic engineering, and discloses a schizochytrium limacinum genetic engineering strain for enhancing supply of acetyl coenzyme A and efficiently producing astaxanthin, a method and application of the schizochytrium limacinum genetic engineering strain. By heterologous expression of a beta-carotene ketolase CrtO gene and a beta-carotene hydroxylase CrtZ gene from haematococcus pluvialis, synthesis of astaxanthin from beta-carotene in schizochytrium limacinum is promoted, so that the content of astaxanthin in schizochytrium limacinum HX-308 is increased. According to the invention, the endogenous AACT gene and heterologous CrtO, CrtZ, PK and PTA genes of schizochytrium limacinum are integrated into an original strain through homologous recombination, and the obtained strain still keeps genetic stability after multiple subculture, has the capability of efficiently synthesizing astaxanthin, effectively improves the yield of astaxanthin, and lays a foundation for large-scale industrial production.

An engineered producer cell comprising an inactivating mutation in one or more endogenous REP binding sites is provided, as are methods for producing the engineered producer cell and using the engineered producer cell to produce a recombinant viral vector and reduce producer cell genomic DNA contamination of a recombinant adeno-associated virus vector preparation.

The invention discloses an oral sleep-aiding composition containing ergothioneine and a preparation method of the oral sleep-aiding composition, and relates to the technical field of sleep-aiding compositions. The oral sleep-aiding composition containing the ergothioneine is prepared from the following components in parts by mass: 0.01 to 3 parts of the ergothioneine, 0.1 to 10 parts of melatonin, 10 to 40 parts of glycine, 2 to 15 parts of magnesium salt, 30 to 70 parts of a diluent, 1 to 10 parts of an adhesive, 0.5 to 5 parts of a lubricant, 2 to 10 parts of a disintegrating agent and 0.1 to 0.5 part of an antioxidant preservative. Through the synergistic compatibility of ergothioneine, melatonin, glycine and magnesium salt, a multi-dimensional action network of oxidation resistance, neuromodulation and receptor inhibition is formed, the limitation of single-component sleep aiding is broken through, and the sleeping efficiency and the sleep maintenance capability are remarkably improved. Based on the scientific proportion of endogenous substances (ergothioneine and glycine), the metabolic burden of traditional sleep-aiding components is avoided, and in combination with the design of a sustained-release preparation, the dose-dependent side effects are reduced, and the safety of long-term taking is improved.

The invention discloses a bifunctional fluorescent molecular probe, a preparation method thereof and application of the bifunctional fluorescent molecular probe in polarity detection of ONOO <-> and lipid droplets, and belongs to the technical field of polarity detection of ONOO <-> and lipid droplets. The problems that a fluorescent probe is only limited to detection of a single analyte, and targeted monitoring of lipid droplets in cells and simultaneous detection of endogenous ONOO <-> in the cells cannot be achieved are solved. According to the invention, a dual-response fluorescent molecular probe PTQ based on a triphenylamine group is prepared, and the PTQ shows dual response to a polar environment and dynamic change of ONOO <->. Test results show that the fluorescent probe shows high sensitivity (1.92 nM), stable fluorescence signals and high quantum yield (57.76%) in a low-polarity medium, also has excellent ONOO <-> selectivity, low detection limit (4.97 nM), low toxicity and excellent biological imaging ability, and realizes targeted monitoring of lipid droplets and detection of endogenous ONOO <-> in cells.

The invention discloses an endogenous small molecule metabolite for treating obesity and related metabolic diseases thereof, and belongs to the field of biological medicine. Specifically, the invention relates to application of hippuric acid in preparation of anti-obesity drugs. The invention discloses a technical scheme for treating obesity and related metabolic disorders by hippuric acid, and overcomes the defects of single curative effect, larger side effect or unclear action mechanism and the like in the prior art through the advantages of targeted improvement of liver fatty degeneration, improvement of insulin sensitivity, higher potential safety, provision of a new treatment strategy and the like. The method has remarkable technical progress and clinical application value.